In the course of our in vivo experiments using BRCA2‐deficient DLD1 and HCT116 cell‐derived xenografts we observed that, in spite of initial inhibition, tumours treated with pyridostatin resumed growth at the end of the treatment (Fig 1B; Appendix Fig S1B). This evidence concerns the gene BRCA2 and neoplasm.